晨光生物(300138.SZ):擬轉讓北京晨光同創所持河北同創30%股權
格隆匯 8 月 10日丨晨光生物(300138.SZ)公佈,公司第四屆董事會第二十一次會議審議通過了《關於孫公司股權轉讓的議案》,為了進一步優化公司集團管理架構,引進行業人才,加快河北同創制藥有限公司(“河北同創”)發展,公司擬將子公司北京晨光同創醫藥研究院有限公司(“北京晨光同創”)所持有的孫公司河北同創30%股權進行轉讓,其中29%股權轉讓給公司全資子公司河北晨光藥業有限公司(“河北晨光藥業”),剩餘1%股權轉讓給引進的合作方。北京晨光同創所持河北同創股權均為認繳股權,尚未實繳,因此此次股權轉讓價格均為0元。各方於2020年8月9日在曲周縣簽署了《股權轉讓協議》。
為了進一步優化公司集團管理架構,引進行業人才,加快河北同創發展,公司決定調整孫公司河北同創的股權結構。此次股權轉讓不會導致公司合併報表範圍發生變化,不會對公司的財務及經營狀況產生不利影響,不存在損害公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.